Skip to main content

Advertisement

Table 2 Baseline patient, angiographic and procedural characteristics according to diabetes status and revascularization assignment

From: Staged complete revascularization or culprit-only percutaneous coronary intervention for multivessel coronary artery disease in patients with ST-segment elevation myocardial infarction and diabetes

Variable No diabetes (n = 834) Diabetes (n = 371)
Culprit-only PCI (n = 422) Staged PCI (n = 412) P value Culprit-only PCI (n = 207) Staged PCI (n = 164) P value
Age (years) 61 (52–70) 58 (50–66) 0.001 61 (53–69) 59 (51–66) 0.055
Male 334 (79.1) 341 (82.8) 0.183 145 (70.0) 135 (82.3) 0.006
Current smoker 225 (53.3) 242 (58.7) 0.115 98 (47.3) 85 (51.8) 0.391
Hypertension 262 (62.1) 233 (56.6) 0.104 140 (67.6) 102 (62.2) 0.275
Dyslipidemia 241 (57.1) 239 (58.0) 0.792 123 (59.4) 107 (65.2) 0.251
Previous myocardial infarction 23 (5.5) 16 (3.9) 0.284 16 (7.7) 10 (6.1) 0.541
Previous PCI 22 (5.2) 20 (4.9) 0.813 16 (7.7) 12 (7.3) 0.881
Previous stroke 43 (10.2) 31 (7.5) 0.176 28 (13.5) 16 (9.8) 0.265
Peripheral vascular disease 8 (1.9) 12 (2.9) 0.337 9 (4.3) 7 (4.3) 0.970
CKD in treatment 13 (3.1) 3 (0.7) 0.013 6 (2.9) 4 (2.4) 1.000
OSAHS 9 (2.1) 5 (1.2) 0.302 2 (1.0) 0 (0) 0.505
Heart rate (beats/min) 76 (69–86) 75 (67–84) 0.010 78 (70–86) 78 (70–85) 0.884
Systolic blood pressure (mmHg) 120 (107–130) 120 (109–130) 0.151 120 (108–130) 120 (110–132) 0.619
Laboratory data
 Peak troponin (μg/L) 68 (25–101) 68 (30–114) 0.076 76 (27–102) 69 (28–108) 0.735
 Peak CK (U/L) 2110 (1088–3391) 2076 (1156–3474) 0.611 1974 (982–3360) 1986 (1012–3311) 0.918
 Peck CK-MB (U/L) 239 (111–304) 217 (128–307) 0.865 180 (89–293) 168 (68–300) 0.963
Time from symptom onset to PCI (h) 5.0 (3.0–8.0) 4.0 (3.0–7.0) 0.004 5.0 (3.0–8.0) 5.0 (3.5–8.0) 0.701
Killip class III/IV 48 (11.4) 26 (6.3) 0.010 31 (15.0) 15 (9.1) 0.091
Radial artery access 192 (45.5) 103 (25.0) < 0.001 101 (48.8) 50 (30.5) < 0.001
No. narrowed coronary arteries    < 0.001    0.082
 Two 317 (75.1) 263 (63.8)   150 (72.5) 105 (64.0)  
 Three 105 (24.9) 149 (36.2)   57 (27.5) 59 (36.0)  
Culprit vessel    0.094    0.003
 Left anterior descending 168 (39.8) 157 (38.1)   88 (42.5) 50 (30.5)  
 Left circumflex 46 (10.9) 66 (16.0)   18 (8.7) 32 (19.5)  
 Right 208 (49.3) 189 (45.9)   101 (48.8) 82 (50.0)  
Non-culprit artery
 Left anterior descending 166 (39.3) 204 (49.5) 0.003 90 (43.5) 88 (53.7) 0.051
 Left circumflex 246 (58.3) 207 (50.2) 0.020 115 (55.6) 82 (50.0) 0.287
 Right 115 (27.3) 151 (36.7) 0.004 58 (28.0) 53 (32.3) 0.369
Thrombus aspiration 284 (67.3) 298 (72.3) 0.114 133 (64.3) 101 (61.6) 0.597
No-reflow phenomenon 46 (10.9) 34 (8.3) 0.194 23 (11.1) 14 (8.5) 0.411
Intra-aortic balloon pump use 30 (7.1) 53 (12.9) 0.006 21 (10.1) 15 (9.1) 0.747
Glycoprotein IIb/IIIa inhibitor use 103 (24.4) 121 (29.4) 0.106 55 (26.6) 36 (22.0) 0.304
Temporary pacemaker 15 (3.6) 5 (1.2) 0.027 12 (5.8) 3 (1.8) 0.054
Defibrillator 24 (5.7) 19 (4.6) 0.483 15 (7.2) 3 (1.8) 0.016
Drug-eluting stent use 405 (96.0) 404 (98.1) 0.077 199 (96.1) 161 (98.2) 0.359
Type of stent    0.280    0.153
 1st drug-eluting stent 314 (74.4) 320 (77.7)   140 (67.6) 125 (76.2)  
 2nd drug-eluting stent 91 (21.6) 84 (20.4)   59 (28.5) 36 (22.0)  
 Bare-mental stent 1 (0.2) 1 (0.2)   2 (1.0) 0 (0)  
 PTCA 16 (3.8) 7 (1.7)   6 (2.9) 3 (1.8)  
Stent number 1 (1–2) 1 (1–2) 0.213 1 (1–2) 1 (1–2) 0.269
Total stent length (mm) 33 (24–51) 31 (24–46) 0.010 33 (24–44) 29 (23–41) 0.141
Minimum stent diameter (mm) 3.0 (2.5–3.5) 3.0 (2.5–3.5) 0.672 3.0 (2.5–3.5) 3.0 (2.5–3.5) 0.561
Medications at discharge
 Aspirin 421 (99.8) 412 (100) 1.000 207 (100) 164 (100) 1.000
 P2Y12 receptor inhibitor 422 (100) 412 (100) 1.000 207 (100) 164 (100) 1.000
 ACEI/ARB 290 (68.7) 327 (79.4) < 0.001 143 (69.1) 126 (76.8) 0.097
 β-blockers 359 (85.1) 334 (81.1) 0.123 185 (89.4) 146 (89.0) 0.915
 Statins 418 (99.1) 408 (99.0) 1.000 207 (100) 163 (99.4) 0.442
Acute kidney injurya 80 (19.1) 97 (23.6) 0.113 37 (18.0) 37 (22.6) 0.272
  1. ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, CKD chronic kidney disease, CK-MB creatine kinase myocardial band, OSAHS obstructive sleep apnea-hypopnea syndrome, PCI percutaneous coronary intervention, PTCA percutaneous transluminal coronary angioplasty
  2. aData of acute kidney injury was obtained from 1200 (99.6%) patients